[global network reporter Zhang Xiaoya] Russian President Vladimir Putin announced on the 11th that the world’s first new crown vaccine has been registered. AFP reported that the World Health Organization said it would like to review the safety data of Russia’s new crown vaccine. “We are in close contact with the Russian health authorities and are discussing the possibility of who prequalification of vaccines,” who spokesman Tarik yasharevicz said at an online news conference in Geneva on the 11th < / P > < p > “prequalification of any vaccine includes a rigorous review and evaluation of all necessary safety and efficacy data.” Yasharevitch said. “Each country has a national regulatory authority that approves the use of vaccines or drugs on its territory,” yasharevicz further explained, “who has implemented prequalification procedures for these vaccines and drugs. Manufacturers require who prequalification because it is a sign of quality assurance. “(and) to achieve this, all safety and effectiveness data collected in clinical trials need to be reviewed and evaluated. Who will do this for any vaccine candidate. ” Not long ago, Putin announced that Russia had registered the first new coronal vaccine, and Russia became the first country in the world to register the new crown vaccine. Russia’s first new crown vaccine was jointly developed by Russia’s gamaliya Research Institute and the Russian Ministry of defense, and was approved by the Russian Ministry of health on the same day on the 11th. Putin said he hoped to start mass production as soon as possible, adding that his daughter had been vaccinated. According to the latest review released by who on July 31, there are 165 vaccine candidates in the world, of which 139 are still under preclinical evaluation, and the remaining 26 are in different stages of human trials. Six of them are far ahead and have reached the third stage of clinical evaluation. The new crown vaccine of Russia is in progress One of the 26 vaccines tested in vivo is currently listed as the first stage (clinical evaluation). Kirill Dmitriev, head of Russia’s Direct Investment Fund (management company), which funds the vaccine project, said the third phase of the trial will start on Wednesday (12th) and is expected to start industrial production in September. At present, more than one billion doses of new coronal vaccine from Russia have been ordered by 20 countries.